Does TRIPTORELIN Cause Malignant neoplasm progression? 75 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 75 reports of Malignant neoplasm progression have been filed in association with TRIPTORELIN (TRIPTODUR). This represents 1.4% of all adverse event reports for TRIPTORELIN.
75
Reports of Malignant neoplasm progression with TRIPTORELIN
1.4%
of all TRIPTORELIN reports
12
Deaths
6
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TRIPTORELIN?
Of the 75 reports, 12 (16.0%) resulted in death, 6 (8.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TRIPTORELIN. However, 75 reports have been filed with the FAERS database.
What Other Side Effects Does TRIPTORELIN Cause?
Off label use (545)
Death (362)
Ovarian hyperstimulation syndrome (356)
Needle issue (242)
Disease progression (203)
Product dose omission issue (178)
Drug ineffective (175)
Weight increased (167)
Hot flush (153)
Headache (145)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TRIPTORELIN Alternatives Have Lower Malignant neoplasm progression Risk?
TRIPTORELIN vs TRISODIUM
TRIPTORELIN vs TROFINETIDE
TRIPTORELIN vs TROFOSFAMIDE
TRIPTORELIN vs TROPATEPINE
TRIPTORELIN vs TROPICAMIDE